Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Chronic Obstructive Pulmonary Disease | Treatment Algorithms | Claims Data Analysis | US | 2014
Chronic obstructive pulmonary disease (COPD) is a disease encompassing chronic bronchitis and emphysema that generally affects smokers and older patients. Current treatment of COPD is dominated by…
What Are the U.S. Market Access and Prescribing Hurdles for the Growing Number of LAMA- and LABA-Containing Competitors in the COPD Market? | Physician & Payer Forum | US | 2014
The U.S. market for chronic obstructive pulmonary disease (COPD) therapies consists entirely of symptomatic treatments, namely bronchodilators and anti-inflammatory agents, which improve patients…
Umeclidinium Bromide Vilanterol (Anoro Ellipta) (COPD) (Wave 1) | LaunchTrends | US | 2014
This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (…
COPD (Positioning of Current and Emerging Agents) | Physician & Payer Forum | Brazil and Mexico | 2014
Improvements in patient access to novel treatments for chronic obstructive pulmonary disease (COPD) in Brazil and Mexico are largely dependent on the expansion of drug coverage by local authorities…
COPD in the EU5: (How Will Prescribers and Payers Integrate Additional LABA- and LAMA-Containing Products Within Increasingly Constrained Budgets?) | Physician & Payer Forum | EU5 | 2014
Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have the potential to be first-line chronic obstructive pulmonary disorder (COPD) therapies…
The Impact of ACOs on Prescribing for Acute Coronary Syndrome and Atrial Fibrillation: Actionable Insights from U.S. Payers and Prescribers | Physician & Payer Forum | US | 2014
Accountable care organizations (ACOs), in which providers are held accountable for the costs of treating a payer’s patent population, will become more the rule than the exception in a year, as…
